| Medicines/Item |
Section |
Status |
Link Name / Link URL |
|
07.04.03 |
Formulary
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA280: Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA146: Adalimumab for the treatment of adults |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Adrenaline / epinephrine |
03.04.03 |
Formulary
|
NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Aflibercept |
08.01.05 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Agomelatine |
04.03.04 |
Non Formulary
|
NICE TA231: Depression - agomelatine (terminated appraisal) |
| Alectinib |
08.01.05 |
Formulary
|
NICE TA536:Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alirocumab |
02.14 |
Restricted Use
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Non Formulary
|
NICE TA156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for AF |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA433 : Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA372: Apremilast for psoriatic arthritis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA433 : Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
| Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526:Arsenic trioxide for treating acute promyelocytic leukaemia |
| Atezolizumab |
08.02.04 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Atezolizumab |
08.02.04 |
Formulary
|
NICE TA584:Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Atezolizumab |
08.02.04 |
Formulary
|
NICE TA520:Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atezolizumab |
08.02.04 |
Formulary
|
NICE TA492:Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Atezolizumab |
08.02.04 |
Formulary
|
NICE TA638:Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Atezolizumab |
08.02.04 |
Formulary
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Avelumab |
08.02.04 |
Formulary
|
NICE TA 517:Avelumab for treating metastatic Merkel cell carcinoma |
| Avelumab |
08.02.04 |
Formulary
|
NIE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Axicabtagene ciloleuce |
08.02.04 |
Formulary
|
NICE TA 559:Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Azithromycin |
05.01.05 |
Formulary
|
NICE ESUOM38 - Non-cystic fibrosis bronchiectasis: long-term azithromycin |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA99: Immunosuppressives in renal transplant (Children) |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA85: Immunosuppressives in renal transplant (Adults) |
| Beclometasone and formoterol |
03.02 |
Formulary
|
NICE Evidence summary [ESNM47]: Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) |
| Bee and Wasp Allergen Extracts |
03.04.02 |
Formulary
|
NICE TA246 : Pharmalgen for the treatment of bee and wasp venom allergy |
| Belimumab |
10.01 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA472Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA263: Breast cancer with capecitabine |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA214: Breast Cancer with taxane |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA589:Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA450:Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Boceprevir |
05.03.03.02 |
Formulary
|
NICE TA253: hepatitis |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: 1st line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum Toxin Type A |
04.09.03 |
Formulary
|
NICE TA260 Migraine (chronic) - botulinum toxin type A |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524:Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA577:Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA594: Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Cangrelor |
02.09 |
Non Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA60: Colorectal cancer - capecitabine and tegafur uracil |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA657: Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Cemiplimab |
08.01 |
Formulary
|
NICE TA592:Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500:Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Cetirizine |
03.04.01 |
Formulary
|
NICE Evidence Summary [ESUOM31]: Chronic urticaria: off-label doses of cetirizine |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Head and neck cancer - cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA176: Colorectal cancer (first line) - cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473:Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA242:Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pani |
| Ciclosporin |
11.99.99.99 |
Non Formulary
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
| Ciclosporin |
11.03.01 |
Formulary
|
NICE TATA369 |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA493:Cladribine tablets for treating relapsing–remitting multiple sclerosis |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA20 Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Colistimethate |
05.01.07 |
Formulary
|
NICE [ESUOM25]Non-cystic fibrosis bronchiectasis: colistimethate sodium |
| Colistimethate for nebulisation |
05.01.07 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase |
10.03.01 |
Formulary
|
NICE TA459:NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
| Daclatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Daclizumab |
08.02.02 |
Formulary
|
NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis |
| Dacomitinib |
08.01.05 |
Formulary
|
NICE TA595:Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes |
| Daratumumab |
08.02.04 |
Formulary
|
NICE TA573:Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Daratumumab |
08.02.04 |
Formulary
|
NICE TA 510:Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
| Darolutamide |
06.04.02 |
Formulary
|
NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer |
| Dasabuvir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA241: CML where treatment with imatinib has failed |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Daunorubicin 44mg and Cytarabine 100mg |
08.01.02 |
Formulary
|
NICE TA552:Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Dexamethasone intravitreal implant |
11.04.01 |
Non Formulary
|
NICE TA349: Diabetic Macular Oedema |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA 475 dimethyl fumarate in plaque psoriasis |
| Dinutuximab |
08.02.04 |
Formulary
|
NICE TA538:Dinutuximab beta for treating neuroblastoma |
| Dipyridamole MR |
02.09 |
Formulary
|
NICE TA20 Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA109: Breast cancer (early) - docetaxel |
| Donepezil |
04.11 |
Formulary
|
NICE TA217 Alzheimers disease - donepezil, galantamine, rivastigmine and memantine |
| Doxorubicin |
08.01.02 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Doxorubicin |
08.01.02 |
Formulary
|
NICE TA440 : Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine |
| Doxorubicin Hydrochloride |
08.01.02 |
Formulary
|
NICE TA 389:Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
| Dupilumab |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Durvalumab |
08.02.04 |
Formulary
|
NICE TA578:Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation |
| Elbasvir/Grazoprevir |
05.03.03.02 |
Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic ITP |
| Eluxadoline |
01.04.02 |
Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for prostate cancer |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Eplerenone |
02.02.03 |
Formulary
|
NICE CG108: Chronic heart failure |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA515:Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572:Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA583:Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA35: Adult psoriasis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA35:Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA348: Preventing Rejection in Liver Transplant |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Evolocumab |
02.14 |
Restricted Use
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exenatide prolonged release |
06.01.02.03 |
Formulary
|
NICE TA248: MR exenatide |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Febuxostat |
10.01.04 |
Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
| Finasteride |
06.04.02 |
Formulary
|
NICE CG97 Lower urinary tract symptoms: quick reference guide |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| Fludrocortisone |
06.03.01 |
Formulary
|
NICE ESUOM20 - Postural hypotension in adults: fludrocortisone |
| Fluticasone furoate & vilanterol |
03.02 |
Formulary
|
NICE Evidence Summary [ESNM34]: Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Galantamine |
04.11 |
Formulary
|
NICE TA217 Alzheimers disease - donepezil, galantamine, rivastigmine and memantine |
| Galcanezumab |
04.07.04.02 |
Formulary
|
NICE TA659: Galcanezumab for preventing |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA25: Pancreatic cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Gilteritinib |
08.01.05 |
Formulary
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE CG32: Glatiramer for the treatment of MS |
| Glecaprevir and Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220:Golimumab for the treatment of psoriatic arthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA225:Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA 521: Guselkumab for treating moderate to severe plaque psoriasis |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA 604: Idelalisib for treating refractory follicular lymphoma |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA70:Guidance on the use of imatinib for chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA326:Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
| Immunocellular therapy containing tisagenlecleucel, autologous T cells genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor (CAR) |
08.02.04 |
Formulary
|
NICE TA554:Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
| Immunocellular therapy containing tisagenlecleucel, autologous T cells genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor (CAR) |
08.02.04 |
Formulary
|
NICE TA567:Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Non Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA497:Golimumab for treating non-radiographic axial spondyloarthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
| Infliximab |
13.05.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Inotuzumab ozogamicin |
08.01 |
Formulary
|
NICE TA541:Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon Alfa - Chronic Hepatitis C |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA32: Interferon Beta for MS |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta |
08.02.04 |
Formulary
|
NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA581:Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Isatuximab |
08.01.05 |
Formulary
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma |
| Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Ivabradine |
02.06.03 |
Formulary
|
NICE guidance on stable angina |
| Ivermectin |
05.05.06 |
Formulary
|
NICE ESUOM29: Difficult-to-treat scabies: oral ivermectin. March 2014 |
| Ixazomib |
08.01.05 |
Formulary
|
NICE TA505:Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis |
| Lamivudine |
05.03.01 |
Formulary
|
NICE CG165: Chronic Hepatitis B |
| Lamivudine |
05.03.01 |
Formulary
|
NICE CG165 : Hepatitis B (chronic): diagnosis and management |
| Lanadelumab |
03.04.03 |
Formulary
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Larotrectinib |
08.01.05 |
Formulary
|
NICE TA 630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA430 : Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA587:Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA586:Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA505:Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322:Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenvatinib |
08.01.05 |
Formulary
|
Lenvatinib with everolimus NICE TA498 |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA535:Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA55:Lenvatinib for untreated advanced hepatocellular carcinoma |
| Letermovir |
05.03.02.02 |
Formulary
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA203: Diabetes (type 2) - liraglutide |
| Lubiprostone |
01.06.07 |
Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lumacaftor + Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Lurasidone |
04.02.01 |
Restricted Use
|
NICE ESNM48: Lurasidone |
| Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Mannitol inhalation |
03.07 |
Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
| Mebeverine |
01.02 |
Formulary
|
NICE CG61 IBS |
| Melatonin |
04.01.01 |
Restricted Use
|
NICE ESUOM2 Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin - 4 January 2013 |
| Memantine |
04.11 |
Formulary
|
NICE TA217 Alzheimers disease - donepezil, galantamine, rivastigmine and memantine |
| Mepolizumab |
03.04.02 |
Formulary
|
NICE TA431 : Mepolizumab for treating severe refractory eosinophilic asthma |
| Metformin |
06.01.02.02 |
Formulary
|
NICE ESUOM6 Polycystic ovary syndrome: metformin in women not planning pregnancy - 26 February 2013 |
| Methylnaltrexone |
01.06.06 |
Formulary
|
NICE TA277: Methylnatrexone for treating opiod-induced bowel dysfunction in people with advanced illness recieving palliative care |
| Methylnaltrexone |
01.06.06 |
Formulary
|
NICE TA468: Methylnatrexone bromide for treating opiod induced constipation |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
| Midodrine |
02.07.02 |
Formulary
|
NICE Evidence Summary: Orthostatic hypotension due to autonomic dysfunction: midodrine |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA523:Midostaurin for untreated acute myeloid leukaemia |
| Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
| Mifepristone |
07.01.02 |
Formulary
|
NICE ESUOM11: mifepristone for induction of labour in late fetal death |
| Milrinone |
02.01.02 |
Non Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Misoprostol |
07.01.01 |
Formulary
|
NICE ESUOM11: Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) |
| Misoprostol |
01.03.04 |
Formulary
|
NICE ESUOM11: Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
| Naldemedine |
01.06.06 |
Formulary
|
NICE TA651: Naldemedine for treating opioid-induced constipation |
| Nalmefene |
04.10.01 |
Formulary
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA345 Naloxegol for treating opioid-induced constipation |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
| Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Neratinib |
08.01.05 |
Formulary
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA347:Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
| Nintedanib |
03.11 |
Non Formulary
|
NICE TA347: Recurrent non-small-cell lung cancer |
| Nintedanib |
03.11 |
Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
| Niraparib |
08.02.04 |
Formulary
|
NICE TA528:Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA558:Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA581:Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA443 : Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA472:Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA 513:Obinutuzumab for untreated advanced follicular lymphoma |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA533:Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA585:Ocrelizumab for treating primary progressive multiple sclerosis |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA472:Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA202:Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
| Olaparib |
08.02.04 |
Formulary
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Olaparib |
08.02.04 |
Formulary
|
NICE TA381: Olaparib guidance |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating allergic asthma |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Ondansetron |
04.06 |
Formulary
|
NICE ESUOM34 : Management of vomiting in children and young people with gastroenteritis: ondansetron – evidence summary unlicensed/off label medicine |
| Opicapone |
04.09.01 |
Non Formulary
|
NICE opicapone – evidence summary (ES9) |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA55:Guidance on the use of paclitaxel in the treatment of ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA108: Breast cancer (early) - paclitaxel |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Formulary
|
NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Pazopanib in renal cell cancer |
| Pegaspargase |
08.01 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA570: Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Pemrolizumab |
08.02.04 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509:Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569:Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pimecrolimus 1% |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| pirfenidone |
03.11 |
Formulary
|
NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy |
| Polatuzumab |
08.01.05 |
Formulary
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA388: Pomalidomide for myeloma |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel |
| Prasugrel |
02.09 |
Formulary
|
NICE TA 182 Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention |
| Promethazine |
03.04.01 |
Formulary
|
NICE evidence summary [ESUOM28]: Rapid tranquillisation in mental health settings: promethazine hydrochloride |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Constipation (women) - prucalopride |
| Quetiapine |
04.02.01 |
Formulary
|
NICE ESUOM12 - Generalised anxiety disorder: quetiapine |
| Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA376: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA160: Osteoporosis - primary prevention |
| Ramipril |
02.05.05.01 |
Formulary
|
NICE evidence summary: Symptoms of peripheral arterial disease: ramipril |
| Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
| Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA448:Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA334:Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA555:Regorafenib for previously treated advanced hepatocellular carcinoma |
| Reslizumab |
03.04.02 |
Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA300:Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA174:Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA193:Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA226:Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA243:Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE ESUOM35: Immune (idiopathic) thrombocytopenic purpura: rituximab – evidence summary |
| Rituximab (rheumatology) |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Rivastigmine |
04.11 |
Formulary
|
NICE TA217 Alzheimers disease - donepezil, galantamine, rivastigmine and memantine |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Rucaparib |
08.01.05 |
Formulary
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril valsartan |
02.15 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA350: Plaque Psoriasis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
| Siponimod |
08.02.04 |
Formulary
|
NICE TA656: Siponimod for treating secondary progressive multiple sclerosis |
| Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
| Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir, Velpatasvir and Voxilaprevir |
05.03.03.02 |
Formulary
|
NICE TA507: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Somatropin for growth failure in children |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA178: Renal cell carcinoma |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA178:Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tadalafil |
07.04.05 |
Formulary
|
NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) |
| Talimogene laherparepvac |
08.02.04 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Talimogene laherparepvec |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03.02 |
Formulary
|
NICE TA252: Telaprevir in hepatitis C |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Temsirolimus |
08.01.05 |
Formulary
|
NICE TA178: Renal cell carcinoma |
| Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for relapsing remitting MS |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Teriparatide |
06.06.01 |
Formulary
|
NICE TA161:Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA228:Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Thiamine |
09.06.02 |
Non Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Thiamine |
09.06.02 |
Non Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA 575: Tildrakizumab for treating |
| Tivozanib |
08.01.05 |
Formulary
|
NICE TA512:Tivozanib for treating advanced renal cell carcinoma |
| Tobramycin inhaler |
05.01.04 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA 238: Tocilizumab in juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA247:Tocilizumab in RA |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA480:NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Tolvaptan |
06.05.02 |
Non Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA544:Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458:Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
| Treosulfan |
08.01.01 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Trifluridine and Tipiracil |
08.01.05 |
Formulary
|
NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Ustekinumab |
10.01.03 |
Formulary
|
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Ustekinumab |
10.01.03 |
Formulary
|
NICE TA340:Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA 456: Ustekinumab for moderately to severe active crohns disease after previous treatment |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Vemurafenib for treating malignant melanoma |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA561:Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Verteporfin |
11.08.02 |
Formulary
|
NICE TA68: Photodynamic therapy for age related macular degeneration |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vortioxetine |
04.03.03 |
Formulary
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
| Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
